The transcription factor CUX1 negatively regulates invasion in castrate resistant prostate cancer

Metastatic prostate cancer is treated with androgen ablation therapy but progress to castrate resistant prostate cancer (CRPC). This study aimed to investigate the role of CUX1 in CRPC using clinical samples and in vitro models. CUX1 expression was increased in androgen-independent cells compared to...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorris, Emma R., O’Neill, Amanda, Treacy, Ann, Klocker, Helmut, Teltsh, Omri, Kay, Elaine, Watson, R. William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061738/
https://www.ncbi.nlm.nih.gov/pubmed/32180898
http://dx.doi.org/10.18632/oncotarget.27494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061738/
https://www.ncbi.nlm.nih.gov/pubmed/32180898
http://dx.doi.org/10.18632/oncotarget.27494

Ejemplares similares